COMMUNIQUÉS West-GlobeNewswire

Prime Biome: We Tested It—Here’s My Honest Prime Biome Review After 117 Days!
03/04/2025
Is Prime Biome’s “gut-skin synergy” the secret to beating bloating, revealing clearer skin, and maintaining steady weight management? Explore real reviews and where to buy. ST. PETERSBURG, Fla., April 03, 2025 (GLOBE [...]
Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel
03/04/2025
CHF 27 million i nvestment signi ficantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer . Boehringer [...]
Novo Nordisk announces changes in Executive Management
03/04/2025
Bagsværd, Denmark, 3 April 2025 – Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with Novo Nordisk, hereof seven years as executive vice president of [...]
LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics
03/04/2025
Press release LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics Access to extensive donor pool supports LIfT’s move into the clinic London, 03 April 2025 [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
03/04/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 3 avril 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
03/04/2025
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under [...]
Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares contre lesquelles il n’existe aucun médicament approuvé
03/04/2025
Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares contre lesquelles il n’existe aucun médicament approuvé Désignation accordée pour l’anémie [...]
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
03/04/2025
Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “ [...]
Veteran Banker Joins Avextra’s Supervisory Board
03/04/2025
News Release Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra’s Supervisory Board, bringing decades of experience in corporate finance, M&A, and [...]
FibroBiologics annonce des progrès scientifiques suite à la confirmation des résultats relatifs à la réparation de tissus cérébraux
03/04/2025
HOUSTON, 03 avr. 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq : FBLG), ou « FibroBiologics », une société de biotechnologie au stade clinique détenant plus de 240 brevets délivrés et en instance portant sur le [...]
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
03/04/2025
Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program 1 [...]
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance
03/04/2025
ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure
03/04/2025
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United [...]
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
02/04/2025
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/04/2025
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
02/04/2025
Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer [...]
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers de l’exercice 2024
02/04/2025
Le programme de développement global de JNJ-1900 (NBTXR3) progresse comme prévu, avec l’opportunité d’adresser l’un des plus grands marchés inexploités en oncologie grâce aux programmes les plus avancés dans le cancer [...]
Range Impact Announces Major Land Acquisition in West Virginia
02/04/2025
CLEVELAND, OHIO, April 02, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing distressed coal mines [...]
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
02/04/2025
Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus on developing [...]

Pages